文献速递细菌感染、耐药与抗菌药物医院感染防控

Accelerate Pheno™系统直接从阳性血培养瓶鉴定和药敏试验多重耐药革兰阴性杆菌的性能评估

Performance of the Accelerate Pheno™ system for identification and antimicrobial susceptibility testing of a panel of multidrug-resistant Gram-negative bacilli directly from positive blood cultures.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

研究用105株已表征β-内酰胺酶基因的临床菌株模拟阳性血培养,平行比较Accelerate Pheno™系统与常规培养法的鉴定和药敏表现。系统总体鉴定一致率100%(105/105),药敏分类一致率94.9%(1169/1232),微小错误4.1%、重大错误0.3%、极重大错误0.7%。作者认为该系统对血流感染多重耐药革兰阴性杆菌的快速鉴定和药敏准确、敏感且易用。

要点

  • Accelerate Pheno™系统与常规法鉴定总体一致率100%(105/105)。
  • 药敏分类一致率94.9%(1169/1232),极重大错误0.7%(8/1232)。
  • 系统对三代头孢菌素酶和碳青霉烯耐药株的提示结果分别为26/26和52/55。

核心结论

  • Accelerate Pheno™系统是血流感染多重耐药革兰阴性杆菌快速鉴定和药敏的准确、敏感且易用的检测方法。
  • 鉴于多重耐药负担,作者认为在微生物实验室实施该系统可能有助于脓毒症的及时管理。

研究设计与样本

  • 研究纳入105株已表征β-内酰胺酶编码基因的临床菌株,覆盖青霉素酶、ESBLs、头孢菌素酶过表达、碳青霉烯酶和通透性降低等耐药谱。
  • 每株约100 cfu接种无菌血培养瓶,在BD BACTEC™ FX自动化系统中孵育至阳性。
  • 阳性血培养瓶平行用Accelerate Pheno™系统和常规培养法检测,常规法用MALDI-TOF和VITEK® 2鉴定、按EUCAST推荐用纸片扩散法和Etest做药敏。
  • 系统在<7 h内直接从阳性血培养瓶报告鉴定和药敏结果。

主要发现

  • Accelerate Pheno™系统与常规培养法总体鉴定一致率为100%(105/105)。
  • 系统与常规药敏总体分类一致率为94.9%(1169/1232),微小错误率4.1%(51/1232),重大错误率0.3%(4/1232),极重大错误率0.7%(8/1232)。
  • 系统产生提示三代头孢菌素酶的结果为26/26,提示碳青霉烯耐药株的结果为52/55。

临床怎么用

  • 作者认为该系统在微生物实验室的实施可能有助于脓毒症的及时管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the performance of the Accelerate Pheno™ system for the identification and antimicrobial susceptibility testing (AST) of a panel of Gram-negative bacilli (GNB) with different resistance profiles (e.g. penicillinases, ESBLs, cephalosporinase overproduction, carbapenemases, impermeability) directly from positive blood cultures in <7 h. METHODS: A panel of 105 clinical strains previously characterized for the presence of β-lactamase-encoding genes was tested. Approximately 100 cfu of each isolate was inoculated into sterile blood culture bottles and incubated in a BD BACTEC™ FX automated system (Becton Dickinson, USA). Positive blood cultures were subjected to parallel testing using the Accelerate Pheno™ system and conventional culture methods [identification of isolated colonies by MALDI-TOF and VITEK® 2 system (bioMérieux, France), and AST by disc diffusion and Etest following EUCAST recommendations]. RESULTS: The overall identification agreement between the Accelerate Pheno™ system and conventional culture methods was 100% (105/105). The overall categorical agreement between the system and culture-based AST was 94.9% (1169/1232), with rates for minor errors of 4.1% (51/1232), major errors 0.3% (4/1232) and very major errors 0.7% (8/1232). The Accelerate Pheno™ system produced AST results indicative of third-generation cephalosporinases (26/26) and carbapenem-resistant strains (52/55). CONCLUSIONS: The Accelerate Pheno™ system is an accurate, sensitive and easy-to-use test for the rapid identification and AST of MDR GNB in bloodstream infections. Given the burden of multidrug resistance, its implementation in the microbiology laboratory could be a useful tool for prompt management of sepsis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pantel A, Monier J, Lavigne JP, et al. Performance of the Accelerate Pheno™ system for identification and antimicrobial susceptibility testing of a panel of multidrug-resistant Gram-negative bacilli directly from positive blood cultures. J Antimicrob Chemother. 2018. PMID: 29474660. doi:10.1093/jac/dky032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。